Currently, two substances with TAAR1 agonistic activity, Ulotaront (SEP-363856, SEP-856, Sunovion Pharmaceuticals Inc.)and Ralmitaront (RG-7906, RO-6889450, F. Hoffmann-La Roche AG), are undergoing clinical trials for the treatment of schizophrenia, schizoaffective disorder, and Parkinson’s disease psychosis [6]. This evidence concerns the gene TAAR1 and schizophrenia.